Lexipafant data

The company reported data from its second Phase II trial in 51 patients with APACHE II scores >5 on entry, showing significantly less organ failure in treated patients.

As reported at the International Congress on Platelet-Activating Factor and Related Lipid Mediators in Berlin, the 27 patients on lexipafant had mean organ failure scores reduced by 1.3 units, whereas scores rose by 0.2 units after placebo (p=0.005). ...